Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025 - 2Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat!
- 3'Senseless violence' erupts at Christmas tree lighting; 4 injured
- 4Building an Individual Brand: Illustrations from Powerhouses
- 5Police break up illegal chicken slaughter in Germany
- Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- Unsold Rams May Be Less expensive Than You Suspect
- Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
- Becoming amazing at Systems administration: Individual and Expert Tips
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
